DK1708679T3 - Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin - Google Patents

Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin

Info

Publication number
DK1708679T3
DK1708679T3 DK04798662T DK04798662T DK1708679T3 DK 1708679 T3 DK1708679 T3 DK 1708679T3 DK 04798662 T DK04798662 T DK 04798662T DK 04798662 T DK04798662 T DK 04798662T DK 1708679 T3 DK1708679 T3 DK 1708679T3
Authority
DK
Denmark
Prior art keywords
hydrofluoroalkane
spray formulation
pharmaceutical spray
acylated cyclodextrin
acylated
Prior art date
Application number
DK04798662T
Other languages
Danish (da)
English (en)
Inventor
Philippe Rogueda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1708679T3 publication Critical patent/DK1708679T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK04798662T 2003-11-26 2004-11-24 Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin DK1708679T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds
PCT/GB2004/004957 WO2005053637A2 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin

Publications (1)

Publication Number Publication Date
DK1708679T3 true DK1708679T3 (da) 2009-02-16

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04798662T DK1708679T3 (da) 2003-11-26 2004-11-24 Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin

Country Status (23)

Country Link
US (1) US20070104652A1 (enExample)
EP (1) EP1708679B1 (enExample)
JP (1) JP4950666B2 (enExample)
KR (1) KR20060118509A (enExample)
CN (1) CN100592908C (enExample)
AT (1) ATE413868T1 (enExample)
AU (1) AU2004294775B2 (enExample)
BR (1) BRPI0416992A (enExample)
CA (1) CA2546441C (enExample)
CY (1) CY1108753T1 (enExample)
DE (1) DE602004017783D1 (enExample)
DK (1) DK1708679T3 (enExample)
ES (1) ES2314469T3 (enExample)
IL (1) IL175659A (enExample)
MX (1) MXPA06005643A (enExample)
NO (1) NO20062969L (enExample)
NZ (1) NZ547355A (enExample)
PL (1) PL1708679T3 (enExample)
PT (1) PT1708679E (enExample)
SE (1) SE0303179D0 (enExample)
SI (1) SI1708679T1 (enExample)
WO (1) WO2005053637A2 (enExample)
ZA (1) ZA200604330B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
JPWO2023127219A1 (enExample) * 2021-12-28 2023-07-06

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW249226B (enExample) * 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
AU2004294775B2 (en) 2007-12-20
ZA200604330B (en) 2007-11-28
HK1108390A1 (zh) 2008-05-09
US20070104652A1 (en) 2007-05-10
JP2007515401A (ja) 2007-06-14
PT1708679E (pt) 2008-12-29
NO20062969L (no) 2006-08-25
CY1108753T1 (el) 2014-04-09
JP4950666B2 (ja) 2012-06-13
SE0303179D0 (sv) 2003-11-26
WO2005053637A3 (en) 2007-06-28
CN101087600A (zh) 2007-12-12
CA2546441C (en) 2011-11-22
DE602004017783D1 (de) 2008-12-24
IL175659A (en) 2010-02-17
CA2546441A1 (en) 2005-06-16
KR20060118509A (ko) 2006-11-23
ES2314469T3 (es) 2009-03-16
ATE413868T1 (de) 2008-11-15
WO2005053637A2 (en) 2005-06-16
EP1708679B1 (en) 2008-11-12
CN100592908C (zh) 2010-03-03
IL175659A0 (en) 2006-09-05
SI1708679T1 (sl) 2009-04-30
BRPI0416992A (pt) 2007-02-06
PL1708679T3 (pl) 2009-04-30
NZ547355A (en) 2009-05-31
EP1708679A2 (en) 2006-10-11
AU2004294775A1 (en) 2005-06-16
MXPA06005643A (es) 2006-08-17

Similar Documents

Publication Publication Date Title
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
CY2015033I1 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
DE60335797D1 (de) Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
DK1319183T3 (da) Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
MXPA03004794A (es) Derivados de acido mandelico y su uso como inhibidores de trombina.
CY1111543T1 (el) Νεες ενωσεις
BRPI0407583A (pt) solução oftálmica lìmpida e estável
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
AU5218001A (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
PL1909843T3 (pl) Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji
IL156470A0 (en) Complex of modafinil and cyclodextrin
PA8579801A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
WO2003066597A3 (en) Guanidino compounds
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
WO2007060512A3 (en) Compositions containing topical active agents and pentylene glycol
AR060072A1 (es) Aerosoles dosificadores para la administracion de preparaciones farmaceuticas
BRPI0413446A (pt) gel bioadesivo á base de hidroxietilcelulose
NO20062548L (no) Intranasale blandinger
NO20076120L (no) Stabile nanopartikkelformuleringer
DK1708679T3 (da) Farmaceutiske sprayformulering, der omfatter en hydrofluoralkan og en acyleret cyclodextrin
AR058141A1 (es) Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas